The Effect of Atazanavir/Cobicistat on the Pharmacokinetics of an Oral Contraceptive Containing Ethinylestradiol and Levonorgestrel (Microgynon 30) in Healthy Women

Trial Profile

The Effect of Atazanavir/Cobicistat on the Pharmacokinetics of an Oral Contraceptive Containing Ethinylestradiol and Levonorgestrel (Microgynon 30) in Healthy Women

Discontinued
Phase of Trial: Phase I

Latest Information Update: 07 Mar 2018

At a glance

  • Drugs Atazanavir/cobicistat (Primary) ; Ethinylestradiol/levonorgestrel (Primary)
  • Indications HIV-1 infections; Pregnancy
  • Focus Pharmacokinetics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 07 Mar 2018 Results presented at the 25th Conference on Retroviruses and Opportunistic Infections
    • 29 Dec 2017 Status changed from recruiting to discontinued.
    • 18 May 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top